Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Personalis, Todos Medical, Invivoscribe, and More

NEW YORK (GenomeWeb) – Personalis this week said that the Parker Institute for Cancer Immunotherapy will use Personalis' ImmunoID Next cancer immunogenomics platform to investigate biomarkers of response to immunotherapies in clinical trial participants. The trials include melanoma, pancreatic, and all-comer solid tumor patients treated with checkpoint inhibitors, either as monotherapy or in combination with other cancer therapies. Earlier this week, Personalis said it signed a research agreement with FLX Bio to use ImmunoID Next to evaluate therapy-related changes in tumors of advanced cancer patients treated with FLX Bio's FLX475 drug.

Todos Medical said this week that it has received approval from the Israeli Ministry of Health to market and sell its TM-B1 and TM-B2 breast cancer screening tests in Israel.

The TM-B1 breast cancer screen is used to detect malignancy, while the TM-B2 breast cancer screen is used to distinguish between benign and malignant tumors in women with probably benign (BI-RADS 3) or suspicious (BI-RADS 4) biopsies. The firm developed the cancer screening tests using its Total Biochemical Infrared Analysis technology, which leverages Fourier transform infrared spectroscopy to analyze test results.

Todos Medical recently inked a distribution agreement for its cancer screens with Care GB in Israel. The agreement, added to the Israeli Ministry of Health approval, has enabled the firm to commercialize its products, and begin sales activities in Austria, Romania, and Israel, the company said.

Invivoscribe said this week that it has acquired additional contiguous space for its accredited Laboratories for Personalized Molecular Medicine — or LabPPMs — in San Diego, Japan, Germany, and China. The company also said it has bolstered its clinical diagnostic test offerings to include morphology, immunohistochemistry, flow cytometry, and multiparameter flow- and next-generation sequencing-based minimal residual disease testing. These new services will further support rapid patient diagnosis, study subject enrollment, and study subject stratifications, the company said. They will be available by the end of this year in San Diego, followed by the laboratories in Japan, Germany, and China.

Thermo Fisher Scientific said this week that its board of directors has declared a quarterly cash dividend of $.19 per common share, payable on July 16 to shareholders of record as of June 14.

Luminex this week announced a cash dividend for the second quarter of $.06 per share, payable on July 11 to stockholders of record as of June 20.

Agilent Technologies this week declared a quarterly dividend of $.16 per share of common stock, payable on July 24 to all shareholders of record as of July 2.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.